Skip to main content
Top
Published in: Current Rheumatology Reports 2/2010

01-04-2010

Remission in Juvenile Idiopathic Arthritis: Current Facts

Authors: Susan Shenoi, Carol A. Wallace

Published in: Current Rheumatology Reports | Issue 2/2010

Login to get access

Abstract

Juvenile idiopathic arthritis (JIA) is the most common chronic inflammatory arthritic disease affecting children. Despite the availability of potent disease-modifying antirheumatic medications, most children still experience a chronic course with long periods of active disease. Goals of treatment should include achievement of disease remission with optimal physical functioning that allows children to lead normal lives with no structural joint damage. The term remission implies a complete lack of disease activity. This article focuses on recently developed preliminary criteria for inactive disease and remission in JIA. Recent studies using these new definitions demonstrate only modest rates of achievement of remission favoring children with persistent oligoarticular JIA. Children with rheumatoid factor-positive polyarticular JIA are least likely to achieve remission. Therapeutic strategies to achieve remission are also discussed.
Literature
1.
go back to reference Packham JC, Hall MA: Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford) 2002, 41:1428–1435.CrossRef Packham JC, Hall MA: Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford) 2002, 41:1428–1435.CrossRef
2.
go back to reference Zak M, Pedersen FK: Juvenile chronic arthritis into adulthood: a long-term follow-up study. Rheumatology (Oxford) 2000, 39:198–204.CrossRef Zak M, Pedersen FK: Juvenile chronic arthritis into adulthood: a long-term follow-up study. Rheumatology (Oxford) 2000, 39:198–204.CrossRef
3.
go back to reference Wallace CA, Levinson JE: Juvenile rheumatoid arthritis: outcome and treatment for the 1990s. Rheum Dis Clin North Am 1991, 17:891–905.PubMed Wallace CA, Levinson JE: Juvenile rheumatoid arthritis: outcome and treatment for the 1990s. Rheum Dis Clin North Am 1991, 17:891–905.PubMed
4.
go back to reference Minden K, Kiessling U, Listing J, et al.: Prognosis of patients with juvenile chronic arthritis and juvenile spondyloarthropathy. J Rheumatol 2000, 27:2256–2263.PubMed Minden K, Kiessling U, Listing J, et al.: Prognosis of patients with juvenile chronic arthritis and juvenile spondyloarthropathy. J Rheumatol 2000, 27:2256–2263.PubMed
5.
go back to reference Oen K, Malleson PN, Cabral DA, et al.: Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol 2002, 29:1989–1999.PubMed Oen K, Malleson PN, Cabral DA, et al.: Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol 2002, 29:1989–1999.PubMed
6.
go back to reference Woo P: Theoretical and practical basis for early aggressive therapy in paediatric autoimmune disorders. Curr Opin Rheumatol 2009, 21:552–557.CrossRefPubMed Woo P: Theoretical and practical basis for early aggressive therapy in paediatric autoimmune disorders. Curr Opin Rheumatol 2009, 21:552–557.CrossRefPubMed
7.
go back to reference • Bartoli M, Taro M, Magni-Manzoni S, et al.: The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis. Ann Rheum Dis 2008, 67:370–374. This study demonstrated that favorable response to methotrexate in JIA helps predict improved long-term outcome.CrossRefPubMed • Bartoli M, Taro M, Magni-Manzoni S, et al.: The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis. Ann Rheum Dis 2008, 67:370–374. This study demonstrated that favorable response to methotrexate in JIA helps predict improved long-term outcome.CrossRefPubMed
8.
go back to reference van Rossum MA, van Soesbergen RM, Boers M, et al.: Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. Ann Rheum Dis 2007, 66:1518–1524.CrossRefPubMed van Rossum MA, van Soesbergen RM, Boers M, et al.: Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. Ann Rheum Dis 2007, 66:1518–1524.CrossRefPubMed
9.
go back to reference Pinals RS, Masi AT, Larsen RA: Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981, 24:1308–1315.CrossRefPubMed Pinals RS, Masi AT, Larsen RA: Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981, 24:1308–1315.CrossRefPubMed
10.
go back to reference van Gestel AM, Prevoo ML, van ’t Hof MA, et al.: Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996, 39:34–40.CrossRefPubMed van Gestel AM, Prevoo ML, van ’t Hof MA, et al.: Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996, 39:34–40.CrossRefPubMed
11.
go back to reference van der Heijde DM, van ’t Hof MA, van Riel PL, et al.: Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990, 49:916–920.CrossRefPubMed van der Heijde DM, van ’t Hof MA, van Riel PL, et al.: Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990, 49:916–920.CrossRefPubMed
12.
go back to reference van der Heijde DM, van ’t Hof MA, van Riel PL, et al.: Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 1992, 51:177–181.CrossRefPubMed van der Heijde DM, van ’t Hof MA, van Riel PL, et al.: Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 1992, 51:177–181.CrossRefPubMed
13.
go back to reference Prevoo ML, van ’t Hof MA, Kuper HH, et al.: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44–48.CrossRefPubMed Prevoo ML, van ’t Hof MA, Kuper HH, et al.: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44–48.CrossRefPubMed
14.
go back to reference Saleem B, Nizam S, Emery P: Can remission be maintained with or without further drug therapy in rheumatoid arthritis? Clin Exp Rheumatol 2006, 24(6 Suppl 43):S33–S36. Saleem B, Nizam S, Emery P: Can remission be maintained with or without further drug therapy in rheumatoid arthritis? Clin Exp Rheumatol 2006, 24(6 Suppl 43):S33–S36.
15.
go back to reference Smolen JS, Aletaha D: What should be our treatment goal in rheumatoid arthritis today? Clin Exp Rheumatol 2006, 24(6 Suppl 43):S7–S13. Smolen JS, Aletaha D: What should be our treatment goal in rheumatoid arthritis today? Clin Exp Rheumatol 2006, 24(6 Suppl 43):S7–S13.
16.
go back to reference Pincus T, Kavanaugh A, Aletaha D, Smolen J: Complexities in defining remission in rheumatic diseases. Clin Exp Rheumatol 2006, 24(6 Suppl 43):S1–S6. Pincus T, Kavanaugh A, Aletaha D, Smolen J: Complexities in defining remission in rheumatic diseases. Clin Exp Rheumatol 2006, 24(6 Suppl 43):S1–S6.
17.
go back to reference Sesin CA, Bingham CO 3rd: Remission in rheumatoid arthritis: wishful thinking or clinical reality? Semin Arthritis Rheum 2005, 35:185–196.CrossRefPubMed Sesin CA, Bingham CO 3rd: Remission in rheumatoid arthritis: wishful thinking or clinical reality? Semin Arthritis Rheum 2005, 35:185–196.CrossRefPubMed
18.
go back to reference Makinen H, Kautiainen H, Hannonen P, Sokka T: Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis 2005, 64:1410–1413.CrossRefPubMed Makinen H, Kautiainen H, Hannonen P, Sokka T: Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis 2005, 64:1410–1413.CrossRefPubMed
19.
go back to reference Molenaar ET, Voskuyl AE, Dinant HJ, et al.: Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 2004, 50:36–42.CrossRefPubMed Molenaar ET, Voskuyl AE, Dinant HJ, et al.: Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 2004, 50:36–42.CrossRefPubMed
20.
go back to reference Prevoo ML, van Gestel AM, van ’t Hof MA, et al.: Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 1996, 35:1101–1105.CrossRefPubMed Prevoo ML, van Gestel AM, van ’t Hof MA, et al.: Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 1996, 35:1101–1105.CrossRefPubMed
21.
go back to reference Fransen J, Creemers MC, Van Riel PL: Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004, 43:1252–1255.CrossRef Fransen J, Creemers MC, Van Riel PL: Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004, 43:1252–1255.CrossRef
22.
go back to reference Mierau M, Schoels M, Gonda G, et al.: Assessing remission in clinical practice. Rheumatology (Oxford) 2007, 46:975–979.CrossRef Mierau M, Schoels M, Gonda G, et al.: Assessing remission in clinical practice. Rheumatology (Oxford) 2007, 46:975–979.CrossRef
23.
go back to reference van Tuyl LH, Vlad SC, Felson DT, et al.: Defining remission in rheumatoid arthritis: results of an initial American College of Rheumatology/European League Against Rheumatism consensus conference. Arthritis Rheum 2009, 61:704–710.CrossRefPubMed van Tuyl LH, Vlad SC, Felson DT, et al.: Defining remission in rheumatoid arthritis: results of an initial American College of Rheumatology/European League Against Rheumatism consensus conference. Arthritis Rheum 2009, 61:704–710.CrossRefPubMed
24.
go back to reference •• Wallace CA, Ruperto N, Giannini E; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group: Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004, 31:2290–2294. Original article, documenting preliminary criteria for remission in JIA.PubMed •• Wallace CA, Ruperto N, Giannini E; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group: Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004, 31:2290–2294. Original article, documenting preliminary criteria for remission in JIA.PubMed
25.
go back to reference • Wallace CA, Ravelli A, Huang B, Giannini EH: Preliminary validation of clinical remission criteria using the OMERACT filter for select categories of juvenile idiopathic arthritis. J Rheumatol 2006, 33:789–795. Original study for validation of remission criteria in JIA.PubMed • Wallace CA, Ravelli A, Huang B, Giannini EH: Preliminary validation of clinical remission criteria using the OMERACT filter for select categories of juvenile idiopathic arthritis. J Rheumatol 2006, 33:789–795. Original study for validation of remission criteria in JIA.PubMed
26.
go back to reference • Wallace CA, Huang B, Bandeira M, et al.: Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum 2005, 52:3554–3562. Retrospective study of JIA patients showing time spent in disease activity states.CrossRefPubMed • Wallace CA, Huang B, Bandeira M, et al.: Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum 2005, 52:3554–3562. Retrospective study of JIA patients showing time spent in disease activity states.CrossRefPubMed
27.
go back to reference Lurati A, Salmaso A, Gerloni V, et al.: Accuracy of Wallace criteria for clinical remission in juvenile idiopathic arthritis: a cohort study of 761 consecutive cases. J Rheumatol 2009, 36:1532–1535.CrossRefPubMed Lurati A, Salmaso A, Gerloni V, et al.: Accuracy of Wallace criteria for clinical remission in juvenile idiopathic arthritis: a cohort study of 761 consecutive cases. J Rheumatol 2009, 36:1532–1535.CrossRefPubMed
28.
go back to reference Fernandes TA, Corrente JE, Magalhaes CS: Remission status follow-up in children with juvenile idiopathic arthritis. J Pediatr (Rio J) 2007, 83:141–148. Fernandes TA, Corrente JE, Magalhaes CS: Remission status follow-up in children with juvenile idiopathic arthritis. J Pediatr (Rio J) 2007, 83:141–148.
29.
go back to reference Ringold S, Seidel KD, Koepsell TD, Wallace CA: Inactive disease in polyarticular juvenile idiopathic arthritis: current patterns and associations. Rheumatology (Oxford) 2009, 48:972–977.CrossRef Ringold S, Seidel KD, Koepsell TD, Wallace CA: Inactive disease in polyarticular juvenile idiopathic arthritis: current patterns and associations. Rheumatology (Oxford) 2009, 48:972–977.CrossRef
30.
go back to reference Russo RA, Katsicas MM: Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents. J Rheumatol 2009, 36:1078–1082.PubMedCrossRef Russo RA, Katsicas MM: Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents. J Rheumatol 2009, 36:1078–1082.PubMedCrossRef
31.
go back to reference Solari N, Viola S, Pistorio A, et al.: Assessing current outcomes of juvenile idiopathic arthritis: a cross-sectional study in a tertiary center sample. Arthritis Rheum 2008, 59:1571–1579.CrossRefPubMed Solari N, Viola S, Pistorio A, et al.: Assessing current outcomes of juvenile idiopathic arthritis: a cross-sectional study in a tertiary center sample. Arthritis Rheum 2008, 59:1571–1579.CrossRefPubMed
32.
go back to reference Magni-Manzoni S, Ruperto N, Pistorio A, et al.: Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis. Arthritis Rheum 2008, 59:1120–1127.CrossRefPubMed Magni-Manzoni S, Ruperto N, Pistorio A, et al.: Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis. Arthritis Rheum 2008, 59:1120–1127.CrossRefPubMed
33.
go back to reference • Foell D, Wulffraat N, Wedderburn LR, et al.: Towards a risk-adapted therapy to maintain clinical remission in juvenile idiopathic arthritis: results of a randomized trial of 6 versus 12 months withdrawal of methotrexate. [abstract 551]. Presented at the American College of Rheumatology Annual Meeting. Philadelphia, PA; October 16–21, 2009. This study looked at duration of methotrexate therapy in ID to determine the risk of relapse. The study also used myeloid-related proteins as a biologic marker to determine the risk for flare in JIA. • Foell D, Wulffraat N, Wedderburn LR, et al.: Towards a risk-adapted therapy to maintain clinical remission in juvenile idiopathic arthritis: results of a randomized trial of 6 versus 12 months withdrawal of methotrexate. [abstract 551]. Presented at the American College of Rheumatology Annual Meeting. Philadelphia, PA; October 16–21, 2009. This study looked at duration of methotrexate therapy in ID to determine the risk of relapse. The study also used myeloid-related proteins as a biologic marker to determine the risk for flare in JIA.
34.
go back to reference • Tynjala P, Vahasalo P, Tarkisinen M, et al.: Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis (A-CUTE-JIA): a multicenter randomized clinical trial. [abstract 2051]. Presented at the American College of Rheumatology Annual Meeting. Philadelphia, PA; October 16–21, 2009. This abstract showed preliminary results from the A-CUTE-JIA, a study that compared three different treatment regimens used for JIA. • Tynjala P, Vahasalo P, Tarkisinen M, et al.: Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis (A-CUTE-JIA): a multicenter randomized clinical trial. [abstract 2051]. Presented at the American College of Rheumatology Annual Meeting. Philadelphia, PA; October 16–21, 2009. This abstract showed preliminary results from the A-CUTE-JIA, a study that compared three different treatment regimens used for JIA.
35.
go back to reference Knowlton N, Jiang K, Frank MB, et al.: The meaning of clinical remission in polyarticular juvenile idiopathic arthritis: gene expression profiling in peripheral blood mononuclear cells identifies distinct disease states. Arthritis Rheum 2009, 60:892–900.CrossRefPubMed Knowlton N, Jiang K, Frank MB, et al.: The meaning of clinical remission in polyarticular juvenile idiopathic arthritis: gene expression profiling in peripheral blood mononuclear cells identifies distinct disease states. Arthritis Rheum 2009, 60:892–900.CrossRefPubMed
36.
go back to reference Prelog M, Schwarzenbrunner N, Tengg E, et al.: Quantitative alterations of CD8+ T cells in juvenile idiopathic arthritis patients in remission. Clin Rheumatol 2009, 28:385–389.CrossRefPubMed Prelog M, Schwarzenbrunner N, Tengg E, et al.: Quantitative alterations of CD8+ T cells in juvenile idiopathic arthritis patients in remission. Clin Rheumatol 2009, 28:385–389.CrossRefPubMed
37.
go back to reference • Magnani A, Pistorio A, Magni-Manzoni S, et al.: Achievement of a state of inactive disease at least once in the first 5 years predicts better outcome of patients with polyarticular juvenile idiopathic arthritis. J Rheumatol 2009, 36:628–634. This study showed that children with JIA who attain ID early on in their disease course tend to have less long-term joint damage.CrossRefPubMed • Magnani A, Pistorio A, Magni-Manzoni S, et al.: Achievement of a state of inactive disease at least once in the first 5 years predicts better outcome of patients with polyarticular juvenile idiopathic arthritis. J Rheumatol 2009, 36:628–634. This study showed that children with JIA who attain ID early on in their disease course tend to have less long-term joint damage.CrossRefPubMed
38.
go back to reference Beukelman T, Guevara JP, Albert DA: Optimal treatment of knee monarthritis in juvenile idiopathic arthritis: a decision analysis. Arthritis Rheum 2008, 59:1580–1588.CrossRefPubMed Beukelman T, Guevara JP, Albert DA: Optimal treatment of knee monarthritis in juvenile idiopathic arthritis: a decision analysis. Arthritis Rheum 2008, 59:1580–1588.CrossRefPubMed
39.
go back to reference Ruperto N, Murray KJ, Gerloni V, et al.: A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004, 50:2191–2201.CrossRefPubMed Ruperto N, Murray KJ, Gerloni V, et al.: A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004, 50:2191–2201.CrossRefPubMed
40.
go back to reference Wallace CA: The use of methotrexate in childhood rheumatic diseases. Arthritis Rheum 1998, 41:381–391.CrossRefPubMed Wallace CA: The use of methotrexate in childhood rheumatic diseases. Arthritis Rheum 1998, 41:381–391.CrossRefPubMed
41.
go back to reference Wallace CA, Sherry DD, Mellins ED, Aiken RP: Predicting remission in juvenile rheumatoid arthritis with methotrexate treatment. J Rheumatol 1993, 20:118–122.PubMed Wallace CA, Sherry DD, Mellins ED, Aiken RP: Predicting remission in juvenile rheumatoid arthritis with methotrexate treatment. J Rheumatol 1993, 20:118–122.PubMed
42.
go back to reference Klein A, Horneff G: Treatment strategies for juvenile idiopathic arthritis. Expert Opin Pharmacother 2009, 10:3049–3060.CrossRefPubMed Klein A, Horneff G: Treatment strategies for juvenile idiopathic arthritis. Expert Opin Pharmacother 2009, 10:3049–3060.CrossRefPubMed
43.
go back to reference Beresford MW, Baildam EM: New advances in the management of juvenile idiopathic arthritis—2. The era of biologicals. Arch Dis Child Educ Pract Ed 2009, 94:151–156.CrossRefPubMed Beresford MW, Baildam EM: New advances in the management of juvenile idiopathic arthritis—2. The era of biologicals. Arch Dis Child Educ Pract Ed 2009, 94:151–156.CrossRefPubMed
44.
go back to reference Hayward K, Wallace CA: Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthritis Res Ther 2009, 11:216.CrossRefPubMed Hayward K, Wallace CA: Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthritis Res Ther 2009, 11:216.CrossRefPubMed
45.
go back to reference Shenoi S, Wallace CA: TNF alpha inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review. Paediatr Drugs 2010 (in press). Shenoi S, Wallace CA: TNF alpha inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review. Paediatr Drugs 2010 (in press).
46.
go back to reference Quinn MA, Conaghan PG, O’Connor PJ, et al.: Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a 12-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005, 52:27–35.CrossRefPubMed Quinn MA, Conaghan PG, O’Connor PJ, et al.: Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a 12-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005, 52:27–35.CrossRefPubMed
47.
go back to reference Boers M: Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum 2003, 48:1771–1774.CrossRefPubMed Boers M: Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum 2003, 48:1771–1774.CrossRefPubMed
48.
go back to reference Moreland LW, Bridges SL Jr: Early rheumatoid arthritis: a medical emergency? Am J Med 2001, 111:498–500.CrossRefPubMed Moreland LW, Bridges SL Jr: Early rheumatoid arthritis: a medical emergency? Am J Med 2001, 111:498–500.CrossRefPubMed
49.
go back to reference O’Dell JR: Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum 2002, 46:283–285.CrossRefPubMed O’Dell JR: Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum 2002, 46:283–285.CrossRefPubMed
50.
go back to reference Breedveld FC, Emery P, Keystone E, et al.: Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 2004, 63:149–155.CrossRefPubMed Breedveld FC, Emery P, Keystone E, et al.: Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 2004, 63:149–155.CrossRefPubMed
Metadata
Title
Remission in Juvenile Idiopathic Arthritis: Current Facts
Authors
Susan Shenoi
Carol A. Wallace
Publication date
01-04-2010
Publisher
Current Science Inc.
Published in
Current Rheumatology Reports / Issue 2/2010
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-010-0085-2

Other articles of this Issue 2/2010

Current Rheumatology Reports 2/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.